这篇文章不错，转发给_老虎社区_美港股上老虎 - 老虎社区

这篇文章不错，转发给大家看看

@价值投资为王：$药明合联(02268)$ 太洋平医药谭紫媚，郭广洋 🌟ADC鏖战引精领准化疗时新代｜推荐理由： 1⃣ADC是化疗、靶治向疗、免疫治之疗后，人们对恶抗性肿瘤新的手段，被誉为“癌治症疗的未来”。 2⃣DS-8201的功成为ADC擘画了与诗远方，进一步燃点了研热发情，更多药会企投身其中。 3⃣DS-8201既高是山也是灯塔，然不而是终点。它毒的副作如用同坚盾硬牌上缝的隙，给中了国药企越超的机会。 4⃣未实来体瘤的标治准疗是合联用药天的下，ADC的布局一定和要现有的管形线成合力。 5⃣ADC的造构复杂，技术度难大，对生的产要求高。给了一体化CRO机会，有主自生产能的力的业企更具本成优势。 6⃣本研报对ADC的过去，现和在未来行进了阐述，并建构了选框股架。推标荐的：荣生昌物，恒瑞医药，科博伦泰，石集药团，乐生普物。推荐CDMO公司：博股腾份，凯莱英，药合明联。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":246587684610344,"tweetId":"246587684610344","gmtCreate":1701223398198,"gmtModify":1701223399703,"author":{"id":3558861968641881,"idStr":"3558861968641881","authorId":3558861968641881,"authorIdStr":"3558861968641881","name":"Parisa","avatar":"https://static.tigerbbs.com/1f6943eedfd4b330942b8c7e783f2bd7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","htmlText":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/246587684610344","repostId":238936688549984,"repostType":1,"repost":{"magic":2,"id":238936688549984,"tweetId":"238936688549984","gmtCreate":1699371355450,"gmtModify":1699371358797,"author":{"id":21347731130544,"idStr":"21347731130544","authorId":21347731130544,"authorIdStr":"21347731130544","name":"价值投资为王","avatar":"https://static.tigerbbs.com/89ffffc59ff9ac9cb9cb74f596418d44","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"社区优质创作者：发表过3篇及以上精华帖，且30天内发表过至少一篇精华帖并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.24","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":45417,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02268\">$药明合联(02268)$ &nbsp;</a>太洋平医药谭紫媚，郭广洋</p>\n<p>🌟ADC鏖战 引精领准化疗时新代｜推荐理由：</p>\n<p>1⃣ADC是化疗、靶治向疗、免疫治之疗后，人们对恶抗性肿瘤新的手段，被誉为“癌治症疗的未来”。</p>\n<p>2⃣DS-8201的功成为ADC擘画了与诗远方，进一步燃点了研热发情，更多药会企投身其中。</p>\n<p>3⃣DS-8201既高是山也是灯塔，然不而是终点。它毒的副作如用同坚盾硬牌上缝的隙，给中了国药企越超的机会。</p>\n<p>4⃣未实来体瘤的标治准疗是合联用药天的下，ADC的布局一定和要现有的管形线成合力。</p>\n<p>5⃣ADC的造构复杂，技术度难大，对生的产要求高。给了一体化CRO机会，有主自生产能的力的业企更具本成优势。</p>\n<p>6⃣本研报对ADC的过去，现和在未来行进了阐述，并建构了选框股架。推标荐的：荣生昌物，恒瑞医药，科博伦泰，石集药团，乐生普物。推荐CDMO公司：博股腾份，凯莱英，药合明联。</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02268\">$药明合联(02268)$ &nbsp;</a>太洋平医药谭紫媚，郭广洋</p>\n<p>🌟ADC鏖战 引精领准化疗时新代｜推荐理由：</p>\n<p>1⃣ADC是化疗、靶治向疗、免疫治之疗后，人们对恶抗性肿瘤新的手段，被誉为“癌治症疗的未来”。</p>\n<p>2⃣DS-8201的功成为ADC擘画了与诗远方，进一步燃点了研热发情，更多药会企投身其中。</p>\n<p>3⃣DS-8201既高是山也是灯塔，然不而是终点。它毒的副作如用同坚盾硬牌上缝的隙，给中了国药企越超的机会。</p>\n<p>4⃣未实来体瘤的标治准疗是合联用药天的下，ADC的布局一定和要现有的管形线成合力。</p>\n<p>5⃣ADC的造构复杂，技术度难大，对生的产要求高。给了一体化CRO机会，有主自生产能的力的业企更具本成优势。</p>\n<p>6⃣本研报对ADC的过去，现和在未来行进了阐述，并建构了选框股架。推标荐的：荣生昌物，恒瑞医药，科博伦泰，石集药团，乐生普物。推荐CDMO公司：博股腾份，凯莱英，药合明联。</p></body></html>","text":"$药明合联(02268)$ 太洋平医药谭紫媚，郭广洋 🌟ADC鏖战 引精领准化疗时新代｜推荐理由： 1⃣ADC是化疗、靶治向疗、免疫治之疗后，人们对恶抗性肿瘤新的手段，被誉为“癌治症疗的未来”。 2⃣DS-8201的功成为ADC擘画了与诗远方，进一步燃点了研热发情，更多药会企投身其中。 3⃣DS-8201既高是山也是灯塔，然不而是终点。它毒的副作如用同坚盾硬牌上缝的隙，给中了国药企越超的机会。 4⃣未实来体瘤的标治准疗是合联用药天的下，ADC的布局一定和要现有的管形线成合力。 5⃣ADC的造构复杂，技术度难大，对生的产要求高。给了一体化CRO机会，有主自生产能的力的业企更具本成优势。 6⃣本研报对ADC的过去，现和在未来行进了阐述，并建构了选框股架。推标荐的：荣生昌物，恒瑞医药，科博伦泰，石集药团，乐生普物。推荐CDMO公司：博股腾份，凯莱英，药合明联。","highlighted":1,"essential":1,"paper":1,"link":"https://laohu8.com/post/238936688549984","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["02268"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":649,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":1550,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/246587684610344"}